MHRA Statement on PATHWAYS Puberty Blocker Trial Safety
The MHRA has issued a statement regarding the PATHWAYS puberty blocker trial, expressing concerns about participant wellbeing and initiating scientific dialogue with the trial sponsor, King's College London. The agency is applying high scrutiny to ensure the safety of potential child and young person participants.
Priority review
Notice
Pharmaceuticals